Otivio

Otivio AS is a privately owned company based in Oslo, Norway. The company was founded in 2010 based on IP, prototypes and clinical data developed at University of Oslo. Otivio is ISO 13485 certified. The core technology enables increased blood flow to the limbs of a patient. Otivio’s main product, FlowOx™, is addressing peripheral arterial disease (PAD), which is a serious condition leading to pain, chronic wounds and in many cases amputation and mortality. The patient population is very large and increasing. There are limited adequate treatment options offered to the patients aside from surgical interventions. FlowOx™ is a non-invasive product intended for home use. Early long-term patient testing documents increased blood flow, reduced pain and wound healing. FlowOx™ is CE marked.

Otivio headquartered in Europe, operates in the Biotechnology, Health Care, Medical Device, Health Diagnostics sector. The company focuses on Biotechnology and has secured $52.6M in funding across 16 round(s). With a team of 1-10 employees, Otivio is actively contributing to advancements in Biotechnology. Their latest funding round, Funding Round - Otivio, raised $3.3M. Discover more about their projects, partnerships, and impact on our platform.